BH3I-1 NEW
| Price | $30 | $39 | $63 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BH3I-1 | CAS No.: 300817-68-9 |
| Purity: 98.2% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BH3I-1 |
| Description | BH3I-1 (BHI1) is a Bcl-2 antagonist. |
| Cell Research | Cells (5×104 cells per well) are seeded into white 96-well plates (Costar) and treated with various concentrations of the compounds for 48 h. For zVAD-FMK protection experiments, cells are preincubated with 100 μM zVAD-FMK for 1 h before the addition of chemicals. Cell viability is determined with an MTS assay. For PI staining experiments, cells are grown in 24-well plates and then incubated with 2 μg ml/L PI. Cell death is determined by FACS analysis.(Only for Reference) |
| In vitro | BH3I-1 inhibits Bcl-xL heterodimerization in vitro. It also induces cytochrome c release[1]. BH3I-1, while inhibiting its reported target Bcl-2/Bim and Bcl-xL/Bim, shows significant inhibition of both the p53/hDM2 and p300/Hif-1a interactions[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 60 mg/mL (149.9 mM) Ethanol : 11 mg/mL (27.5 mM) |
| Keywords | MDM-2/p53 | BH3I 1 | BHI-1 | Inhibitor | Ubiquitin ligase | E3 ligating enzyme | Ubiquitin conjugating enzyme | BH3I1 | BH3I-1 | E2 conjugating enzyme | Bcl-2 Family | E1 activating enzyme | inhibit | BH 3I1 | E1/E2/E3 Enzyme | BHI 1 | Ubiquitin activating enzyme | BH-3I-1 |
| Inhibitors Related | (S)-(+)-Ibuprofen | Nutlin-3 | NAcM-OPT | Navitoclax | Gossypol | Triacetylresveratrol | Diphenyl disulfide | Lisaftoclax | NSC232003 | NAE-IN-M22 | Venetoclax | Indole-3-carbinol |
| Related Compound Libraries | Glycometabolism Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Autophagy Compound Library | Anti-Parkinson's Disease Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-05 | |
| $50.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-20 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY